Leerink Partnrs Lowers Earnings Estimates for AC Immune

AC Immune SA (NASDAQ:ACIU) – Investment analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for AC Immune in a research note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $0.06 for the year, down from their prior estimate of $0.12. The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share.

A number of other research firms have also recently weighed in on ACIU. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AC Immune in a report on Wednesday. StockNews.com lowered AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Stock Up 5.8 %

NASDAQ ACIU opened at $3.27 on Thursday. AC Immune has a 1-year low of $2.25 and a 1-year high of $5.14. The company has a 50 day moving average of $3.27 and a 200-day moving average of $3.45.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.67). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $91.60 million.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Redmile Group LLC increased its stake in shares of AC Immune by 0.4% in the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock valued at $5,941,000 after buying an additional 7,031 shares during the period. Renaissance Technologies LLC increased its position in AC Immune by 26.4% in the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after purchasing an additional 136,300 shares during the period. Assenagon Asset Management S.A. raised its holdings in AC Immune by 294.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after purchasing an additional 328,312 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in AC Immune during the 2nd quarter valued at about $218,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after purchasing an additional 7,400 shares during the last quarter. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.